Zobrazeno 1 - 10
of 937
pro vyhledávání: '"leukemic stem cells"'
Autor:
Yi Zhang, Miso Park, Lucy Y. Ghoda, Dandan Zhao, Melissa Valerio, Ebtesam Nafie, Asaul Gonzalez, Kevin Ly, Bea Parcutela, Hyeran Choi, Xubo Gong, Fang Chen, Kaito Harada, Zhenhua Chen, Le Xuan Truong Nguyen, Flavia Pichiorri, Jianjun Chen, Joo Song, Stephen J. Forman, Idoroenyi Amanam, Bin Zhang, Jie Jin, John C. Williams, Guido Marcucci
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-18 (2024)
Abstract Background The interleukin-1 receptor accessory protein (IL1RAP) is highly expressed on acute myeloid leukemia (AML) bulk blasts and leukemic stem cells (LSCs), but not on normal hematopoietic stem cells (HSCs), providing an opportunity to t
Externí odkaz:
https://doaj.org/article/81c6c4a1c88f4c5d9d2eee24813cc8c0
Publikováno v:
International Journal of Translational Medicine, Vol 4, Iss 2, Pp 354-368 (2024)
Tyrosine kinase inhibitors (TKIs), such as imatinib (IM), increase the survival of chronic myeloid leukemia (CML) patients but do not eradicate the disease as leukemia stem cells (LSCs) with primitive and quiescent signatures persist after TKI monoth
Externí odkaz:
https://doaj.org/article/7634c85c657d4850b5341db0698fea94
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 59, Iss , Pp 101084- (2025)
Leukemia stem cells (LSCs) play a critical role in the initiation, recurrence, and resistance to treatment of leukemia. Eradicating LSCs is crucial for the complete elimination of the disease. CD45RA is identified as an important marker for LSC subse
Externí odkaz:
https://doaj.org/article/e7843a727c154e5db7836cd6797dfdc6
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionAcute myeloid leukemia (AML) is the most common acute leukemia in adults with an overall poor prognosis and high relapse rate. Multiple factors including genetic abnormalities, differentiation defects and altered cellular metabolism contr
Externí odkaz:
https://doaj.org/article/fb5325fe89af4b1a9b46b685a4c97a0a
Publikováno v:
Heliyon, Vol 9, Iss 11, Pp e22091- (2023)
This study explores the therapeutic potential of targeting CXCR2 in patients afflicted with ponatinib-resistant chronic myeloid leukemia (CML). Ponatinib, a third-generation tyrosine kinase inhibitor (TKI), was initially designed for treating patient
Externí odkaz:
https://doaj.org/article/bdee0f2a553c47d785ebb94b3624de6a
Publikováno v:
Hematology, Vol 27, Iss 1, Pp 706-713 (2022)
Objective Acute lymphoblastic leukemia is the most common malignant disease in children. CD34 and CD38 are expressed in both normal and leukemia cells, but studies of their prognostic associations in childhood acute lymphoblastic leukemia are limited
Externí odkaz:
https://doaj.org/article/fc5dd74c41ce48ff880786d5757f7f3b
Autor:
Henrike Jacobi, Margherita Vieri, Marlena Bütow, Carolina Y. Namasu, Laura Flüter, Ivan G. Costa, Tiago Maié, Katharina Lindemann-Docter, Nicolas Chatain, Fabian Beier, Michael Huber, Wolfgang Wagner, Martina Crysandt, Tim H. Brümmendorf, Mirle Schemionek
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
The management of patients with chronic myeloid leukemia (CML) has been revolutionized by the introduction of tyrosine kinase inhibitors (TKIs), which induce deep molecular responses so that treatment can eventually be discontinued, leading to treatm
Externí odkaz:
https://doaj.org/article/1bcfdb9e48a74693a9367baef6ba229c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Yanan Zhai, Prashant Singh, Anna Dolnik, Peter Brazda, Nader Atlasy, Nunzio del Gaudio, Konstanze Döhner, Hartmut Döhner, Saverio Minucci, Joost Martens, Lucia Altucci, Wout Megchelenbrink, Lars Bullinger, Hendrik G. Stunnenberg
Publikováno v:
Molecular Cancer, Vol 21, Iss 1, Pp 1-15 (2022)
Abstract Background Acute myeloid leukemia (AML) is a heterogeneous and aggressive blood cancer that results from diverse genetic aberrations in the hematopoietic stem or progenitor cells (HSPCs) leading to the expansion of blasts in the hematopoieti
Externí odkaz:
https://doaj.org/article/cdc5c6225a8845a29d882f5c207da3a3
Autor:
Laurène Pousse, Koorosh Korfi, Bruno C. Medeiros, Marco Berrera, Nadine Kumpesa, Jan Eckmann, Idil Karakoc Hutter, Vera Griesser, Vaios Karanikas, Christian Klein, Maria Amann
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundAcute Myeloid leukemia is a heterogeneous disease that requires novel targeted treatment options tailored to the patients’ specific microenvironment and blast phenotype.MethodsWe characterized bone marrow and/or blood samples of 37 AML pa
Externí odkaz:
https://doaj.org/article/26b1cfeae8be48eea4e271097d31fc49